What is Systemic Lupus Erythematosus (SLE)?
SLE is a chronic multisystem autoimmune disease characterized by loss of immune tolerance to nuclear antigens, immune complex-mediated tissue injury, and type I interferon-driven inflammation, predominantly affecting women (90% of cases) with variable presentation across multiple organ systems 1, 2.
The disease involves:
- Autoantibody production against nuclear components leading to immune complex deposition
- Inflammation affecting skin, joints, kidneys, blood cells, cardiovascular, pulmonary, and neurologic systems
- Relapsing-remitting course in approximately 70% of patients, with the remainder split between prolonged remission and persistently active disease 3
How is SLE Diagnosed?
Diagnosis requires a positive antinuclear antibody (ANA) titer of ≥1:80 as an obligatory entry criterion, combined with clinical manifestations across multiple organ systems 4, 5.
Key Diagnostic Elements:
Clinical Features to Identify:
- Constitutional: Fever, fatigue, weight loss
- Mucocutaneous: Malar rash, discoid lesions, photosensitivity, oral ulcers, alopecia
- Musculoskeletal: Non-erosive arthritis, arthralgia
- Renal: Proteinuria >0.5g/24h, active urinary sediment (indicating lupus nephritis in 40% of patients)
- Hematologic: Cytopenia (leukopenia, lymphopenia, thrombocytopenia, hemolytic anemia)
- Cardiopulmonary: Serositis (pleuritis, pericarditis)
- Neuropsychiatric: Seizures, psychosis, cognitive dysfunction
Laboratory Criteria:
- ANA ≥1:80 (mandatory)
- SLE-specific autoantibodies: Anti-dsDNA, anti-Smith antibodies
- Low complement levels: C3, C4 (indicating active disease)
- Antiphospholipid antibodies: Lupus anticoagulant, anticardiolipin, anti-β2-glycoprotein I
The 2019 EULAR/ACR classification criteria are 96.1% sensitive and 93.4% specific for SLE 1, though these are technically classification rather than diagnostic criteria—use them with clinical judgment 3.
Common Diagnostic Pitfall:
Do not rely solely on ANA positivity; ANA can be positive in healthy individuals and other conditions. The pattern of organ involvement plus specific autoantibodies (anti-dsDNA, anti-Smith) confirms the diagnosis 2.
How is a Flare Recognized?
A flare is identified by new or worsening clinical manifestations in any organ system, often accompanied by rising anti-dsDNA titers, falling complement levels (C3/C4), and increased inflammatory markers 4.
Flare Recognition Algorithm:
Clinical Indicators:
- New symptoms: Rash, arthritis, serositis, fever without infection
- Worsening existing manifestations: Increased proteinuria, rising creatinine (renal flare), new cytopenias
- Constitutional symptoms: Fatigue, malaise disproportionate to baseline
Laboratory Changes:
- Rising anti-dsDNA antibodies
- Falling complement (C3, C4)
- New or worsening proteinuria
- Active urinary sediment (RBC casts, dysmorphic RBCs)
- Cytopenias
Flare Severity Classification:
- Mild flares: Manageable with dose adjustments of current therapy
- Moderate flares: Require addition of new immunosuppressive agents
- Severe/major flares: Life-threatening or organ-threatening, requiring aggressive immunosuppression 6
Important caveat: Distinguish true disease flares from infection, medication side effects, or cumulative organ damage—serologically active but clinically quiescent disease may not require treatment escalation 6.
How is SLE Treated?
Treatment aims at achieving remission or low disease activity with the lowest possible glucocorticoid dose, using hydroxychloroquine as universal foundation therapy for all patients unless contraindicated 4, 1.
Treatment Algorithm:
Universal Foundation Therapy:
Hydroxychloroquine (HCQ) for ALL patients 4, 1, 5:
- Dose: ≤5 mg/kg actual body weight daily
- Benefits: Reduces mortality, prevents flares, prevents organ damage, reduces thrombosis risk
- Monitoring: Ophthalmologic screening at baseline, after 5 years, then yearly (visual fields and/or spectral domain-OCT) 4
Glucocorticoid Strategy:
Minimize glucocorticoids aggressively—target <7.5 mg/day prednisone equivalent, with goal of complete withdrawal when possible 4:
- Acute severe disease: IV methylprednisolone pulses (250-1000 mg/day for 1-3 days) provide immediate effect and allow lower starting oral doses 4
- Maintenance: Taper to <7.5 mg/day prednisone equivalent as quickly as possible
- Add immunomodulatory agents early to expedite glucocorticoid tapering 4
Critical warning from CORTICOLUP trial: Patients on chronic prednisone 5 mg/day who discontinued had higher flare rates versus those continuing—taper slowly only after achieving long-standing remission 6.
Immunosuppressive Therapy by Disease Severity:
Mild-Moderate Disease:
- Methotrexate or azathioprine for arthritis, skin manifestations
- Continue HCQ
- Minimize glucocorticoids
Moderate-Severe Disease (Organ-Threatening):
Two-phase approach 4:
Phase 1 - Induction (high-intensity, 3-6 months):
- Mycophenolate mofetil OR cyclophosphamide (for lupus nephritis or severe manifestations)
- High-dose glucocorticoids (with rapid taper)
- Continue HCQ
Phase 2 - Maintenance (consolidation, years):
- Mycophenolate mofetil or azathioprine
- Minimal glucocorticoids (<7.5 mg/day or discontinued)
- Continue HCQ
Biologic Therapies (FDA-Approved):
Belimumab 1:
- Approved for active SLE (2011) and lupus nephritis (2020)
- Add to standard therapy for inadequate response
Anifrolumab 1:
- Approved for active SLE
- Type I interferon receptor antagonist
Voclosporin 1:
- Approved specifically for lupus nephritis
- Calcineurin inhibitor for "multitargeted" therapy
Lupus Nephritis-Specific Treatment:
Induction: Mycophenolate mofetil OR cyclophosphamide + glucocorticoids + HCQ, with goal of complete renal remission (proteinuria <0.5g/24h, normal/stable creatinine) 4, 1
Maintenance: Mycophenolate mofetil or azathioprine for years to prevent relapses
Approximately 10% progress to end-stage kidney disease after 10 years despite treatment 1.
Treatment Targets:
Primary goal: Remission or Low Lupus Disease Activity State (LLDAS) 6, 4:
- Minimal symptoms
- Low autoimmune inflammatory markers
- Minimal glucocorticoid requirement (≤7.5 mg/day)
- No new organ damage
Achieving these targets reduces organ damage accumulation (SDI) with odds ratios of 0.49-0.75 for remission and 0.19-0.88 for LLDAS 6.
Flare Management:
Adjust treatment intensity based on flare severity 4:
- Mild: Increase current medication doses
- Moderate: Add new immunosuppressive agent
- Severe: IV methylprednisolone pulses + aggressive immunosuppression
Critical Management Principles:
Never discontinue hydroxychloroquine—multiple large observational studies show 1.56-2.30 times higher flare rates after HCQ discontinuation 6. If dose reduction necessary, taper gradually rather than abrupt cessation (45.9% vs 72.6% flare rates) 6.
Glucocorticoid withdrawal is safer than HCQ withdrawal when done gradually in patients with long-standing remission, though still carries flare risk 6.
Preventive measures: All patients should receive vaccinations including recombinant zoster vaccine (Shingrix) and COVID-19 vaccination—flare rates are low (7.1-17% mild flares with zoster vaccine) 6.